Dahl Douglas M, Wu Shulin, Lin Sharron X, Hu Mengjie, Barney Alfred A, Kim Michelle M, Cornejo Kristine M, Harisinghani Mukesh G, Feldman Adam S, Wu Chin-Lee
Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Urol Oncol. 2024 Feb;42(2):28.e21-28.e28. doi: 10.1016/j.urolonc.2023.11.004. Epub 2024 Jan 4.
Multiparametric magnetic resonance imaging (mpMRI) of the prostate has excellent sensitivity in detecting clinically significant prostate cancer (csCaP). However, whether a negative mpMRI in patients with a clinical suspicion of CaP can omit a confirmatory biopsy remains less understood and without consensus. Transperineal (TP) standard template biopsy (SBx) provides an effective approach to CaP detection. Our aim is to provide a comprehensive understanding of the CaP characteristics detected through TP SBx that are systematically overlooked by mpMRI.
We conducted a retrospective analysis of all men who underwent prebiopsy mpMRI and subsequent a 20-core TP SBx at our hospital from September 2019 to February 2021. Patients with suspicious mpMRI received a combined TP SBx and targeted biopsy (TBx) (suspicious group), while those without suspicious (negative) mpMRI and who proceeded to biopsy, received TP SBx only (nonsuspicious group). A negative mpMRI was defined as the absence of suspicious findings and/or the presence of low-risk areas with a PI-RADS score of ≤2. Subsequently, we compared and evaluated the clinical and biopsy characteristics between these 2 groups.
We identified 301 men in suspicious group and 215 men in nonsuspicious group. The overall CaP detection rate and csCaP detection rate by TP SBx were 74.1%, 38.9% for suspicious group and 43.3%, 14.9% for nonsuspicious group, respectively. csCaP NPV of mpMRI was 85.1% with a csCaP prevalence 28.9%. The greatest percentage of cancer involvement (GPC) in biopsy core from nonsuspicious group was significantly lower than those of suspicious group (40% vs. 50%, p = 0.005), In multivariate logistic analysis, only PSAD > 0.15 ng/ml/cc was identified as an independent and significant predictor of csCaP in nonsuspicious group.
Within our cohort, false-negative rates of mpMRI for csCaP are substantial, reaching 15%. Nonsuspicious cases may contain a large volume tumor since the high GPC of SBx. For cases with nonsuspicious imaging and higher PSAD, a confirmatory biopsy may be necessary due to the increased risk of missed csCaP by mpMRI.
前列腺多参数磁共振成像(mpMRI)在检测临床显著前列腺癌(csCaP)方面具有出色的敏感性。然而,对于临床怀疑患有前列腺癌(CaP)的患者,mpMRI结果为阴性时是否可以省略确诊性活检,目前仍了解较少且未达成共识。经会阴(TP)标准模板活检(SBx)为CaP检测提供了一种有效方法。我们的目的是全面了解通过TP SBx检测到的、mpMRI系统漏诊的CaP特征。
我们对2019年9月至2021年2月在我院接受活检前mpMRI及随后20针TP SBx的所有男性进行了回顾性分析。mpMRI可疑的患者接受TP SBx联合靶向活检(TBx)(可疑组),而mpMRI无可疑(阴性)且进行活检的患者仅接受TP SBx(非可疑组)。mpMRI阴性定义为无可疑发现和/或存在PI-RADS评分≤2的低风险区域。随后,我们比较并评估了这两组之间的临床和活检特征。
我们确定可疑组有301名男性,非可疑组有215名男性。TP SBx的总体CaP检出率和csCaP检出率在可疑组分别为74.1%、38.9%,在非可疑组分别为43.3%、14.9%。mpMRI的csCaP阴性预测值为85.1%,csCaP患病率为28.9%。非可疑组活检核心中最大癌症累及百分比(GPC)显著低于可疑组(40%对50%,p = 0.005)。在多因素逻辑分析中,仅前列腺特异抗原密度(PSAD)> 0.15 ng/ml/cc被确定为非可疑组中csCaP的独立且显著预测因素。
在我们的队列中,mpMRI对csCaP的假阴性率相当高,达到15%。由于SBx的GPC高,非可疑病例可能包含大体积肿瘤。对于影像学无可疑且PSAD较高的病例,由于mpMRI漏诊csCaP的风险增加,可能需要进行确诊性活检。